Last ¥1,130 JPY
Change Today +27.00 / 2.45%
Volume 1.6M
4151 On Other Exchanges
Symbol
Exchange
Tokyo
OTC US
Munich
As of 2:00 AM 06/19/13 All times are local (Market data is delayed by at least 15 minutes).

kyowa hakko kirin co ltd (4151) Snapshot

Open
¥1,130
Previous Close
¥1,103
Day High
¥1,150
Day Low
¥1,104
52 Week High
05/15/13 - ¥1,256
52 Week Low
06/20/12 - ¥781.00
Market Cap
651.4B
Average Volume 10 Days
2.4M
EPS TTM
¥47.82
Shares Outstanding
576.5M
EX-Date
06/26/13
P/E TM
23.6x
Dividend
¥25.00
Dividend Yield
1.77%
Current Stock Chart for KYOWA HAKKO KIRIN CO LTD (4151)

Related News

No related news articles were found.

kyowa hakko kirin co ltd (4151) Related Businessweek News

No Related Businessweek News Found

kyowa hakko kirin co ltd (4151) Details

Kyowa Hakko Kirin Co., Ltd., together with its subsidiaries, engages in the manufacture and marketing of pharmaceuticals and bio-chemicals in Asia, Europe, and the United States. The company’s Pharmaceuticals segment is involved in the research, development, production, and sale of ethical drugs by utilizing therapeutic antibodies for the treatment of various diseases, including oncology diseases, allergies, renal anemia, and hypertension. Its ethical drugs include ESPO/NESP, an ESA formulation; REGPARA, a secondary hyperparathyroidism; ALLELOCK, an antiallergic agent; Patanol antiallergic eye drops; GRAN, G-CSF agent; 5-FU, an anticancer agent; CONIEL, a hypertension and angina pectoris; DEPAKENE, an antiepileptic agent; Fentos, a transdermal analgesic; and Romiplate, a chronic idiopathic thrombocytopenic purpur. This segment also engages in the manufacture and sale of Determiner series clinical chemistry diagnostic reagents; discovery of new drug candidates; and licensing POTELLIGENT and COMPLEGENT antibody technologies. The company’s Bio-chemicals segment engages in the production and sale of fine chemical and healthcare products for use in pharmaceuticals and their intermediates, health foods, dietary supplements, and cosmetics. Its fine chemical products include amino acids, nucleic acids, and related compounds; and healthcare products comprise amino acids, vitamins, minerals, carotins, peptides, and Remake and Enguard series products. This segment is also involved in the production of plant growth regulators; import, export, and sale of amino acids and fine chemicals; sale of healthcare products; design and installation of equipment and facilities; and mail-order sale of healthcare products in Japan. In addition, the company engages in logistics, insurance, and food wholesaling businesses. The company was founded in 1949 and is headquartered in Tokyo, Japan. Kyowa Hakko Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.

7,243 Employees
Last Reported Date: 03/15/13
Founded in 1949

kyowa hakko kirin co ltd (4151) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

kyowa hakko kirin co ltd (4151) Key Developments

Kyowa Hakko Kirin Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending December 31, 2013

Kyowa Hakko Kirin Co., Ltd. provided dividend guidance for the fiscal year ending December 31, 2013. For the period, the company expects to pay interim dividend of JPY 12.50 per share and year end dividend of JPY 12.50 per share compared to interim dividend of JPY 10.00 per share and year end dividend of JPY 10.00 per share paid in the same period a year ago.

Kyowa Hakko Kirin Co., Ltd. Reports Consolidated Earnings Results for the First Quarter Ended March 31, 2013; Provides Earnings Guidance for the Six Months Ending June 30, 2013 and Year Ending December 31, 2013

Kyowa Hakko Kirin Co., Ltd. reported consolidated earnings results for the first quarter ended March 31, 2013. For the period, the company reported net sales were ¥86,669 million against ¥87,111 million a year ago. Operating income was ¥14,465 million against ¥14,465 million against ¥18,039 million a year ago. Net income was ¥10,489 million against ¥8,514 million a year ago. Fully diluted per share was ¥19.15 against ¥15.45 a year ago. Income before income taxes and minority interest was ¥18,656 million against ¥16,250 million a year ago. For the six months ending June 30, 2013, the company expects net sales of ¥169,000 million, operating income of ¥29,000 million. For the year ending December 31, 2013, the company expects net sales of ¥338,000 million, operating income of ¥55,000 million, net income of ¥30,000 million.

Kyowa Hakko Kirin Co., Ltd. Presents at Daiwa Investment Conference Tokyo 2013, Mar-04-2013

Kyowa Hakko Kirin Co., Ltd. Presents at Daiwa Investment Conference Tokyo 2013, Mar-04-2013 . Venue: The Prince Park Tower Tokyo, Tokyo, Japan.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4151:JP ¥1,130.00 JPY +27.00

4151 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $36.69 USD -0.82
Albemarle Corp $63.77 USD -0.22
Biogen Idec Inc $206.66 USD -4.14
Bristol-Myers Squibb Co $46.42 USD -0.4299
UCB SA €39.47 EUR -0.135
View Industry Companies
 

Industry Analysis

4151

Industry Average

Valuation 4151 Industry Range
Price/Earnings 23.4x
Price/Sales 1.8x
Price/Book 1.1x
Price/Cash Flow 14.8x
TEV/Sales 1.8x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KYOWA HAKKO KIRIN CO LTD, please visit www.kyowa-kirin.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.